CN107898651A - A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof - Google Patents
A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof Download PDFInfo
- Publication number
- CN107898651A CN107898651A CN201711094247.4A CN201711094247A CN107898651A CN 107898651 A CN107898651 A CN 107898651A CN 201711094247 A CN201711094247 A CN 201711094247A CN 107898651 A CN107898651 A CN 107898651A
- Authority
- CN
- China
- Prior art keywords
- wet tissue
- ammonium salt
- quaternary ammonium
- organosilicon
- acrylamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004745 nonwoven fabric Substances 0.000 title claims abstract description 68
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims description 52
- 239000007788 liquid Substances 0.000 claims abstract description 55
- -1 alkyl glucosides Chemical class 0.000 claims abstract description 20
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 12
- 229930182478 glucoside Natural products 0.000 claims abstract description 12
- 239000000787 lecithin Substances 0.000 claims abstract description 12
- 229940067606 lecithin Drugs 0.000 claims abstract description 12
- 235000010445 lecithin Nutrition 0.000 claims abstract description 12
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical class CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000003643 water by type Substances 0.000 claims abstract description 11
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 8
- 230000003750 conditioning effect Effects 0.000 claims abstract description 8
- 239000000178 monomer Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical group CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims description 8
- 229940048848 lauryl glucoside Drugs 0.000 claims description 8
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 7
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 7
- 241001330002 Bambuseae Species 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 7
- 239000011425 bamboo Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229910004664 Cerium(III) chloride Inorganic materials 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000007654 immersion Methods 0.000 claims description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 5
- 229940106189 ceramide Drugs 0.000 claims description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 230000005260 alpha ray Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 125000001549 ceramide group Chemical group 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 238000010894 electron beam technology Methods 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 150000008131 glucosides Chemical class 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 abstract description 16
- 230000002335 preservative effect Effects 0.000 abstract description 16
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 6
- 208000026935 allergic disease Diseases 0.000 abstract description 6
- 230000007815 allergy Effects 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 16
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000001294 propane Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 3
- 229940073769 methyl oleate Drugs 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000012975 dibutyltin dilaurate Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102100036789 Protein TBATA Human genes 0.000 description 1
- 101710118245 Protein TBATA Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000085595 Zizania latifolia Species 0.000 description 1
- 235000004259 Zizania latifolia Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical group C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical group [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- YWFWDNVOPHGWMX-UHFFFAOYSA-N n,n-dimethyldodecan-1-amine Chemical compound CCCCCCCCCCCCN(C)C YWFWDNVOPHGWMX-UHFFFAOYSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940079781 sodium cocoyl glutamate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M14/00—Graft polymerisation of monomers containing carbon-to-carbon unsaturated bonds on to fibres, threads, yarns, fabrics, or fibrous goods made from such materials
- D06M14/18—Graft polymerisation of monomers containing carbon-to-carbon unsaturated bonds on to fibres, threads, yarns, fabrics, or fibrous goods made from such materials using wave energy or particle radiation
- D06M14/20—Graft polymerisation of monomers containing carbon-to-carbon unsaturated bonds on to fibres, threads, yarns, fabrics, or fibrous goods made from such materials using wave energy or particle radiation on to materials of natural origin
- D06M14/22—Graft polymerisation of monomers containing carbon-to-carbon unsaturated bonds on to fibres, threads, yarns, fabrics, or fibrous goods made from such materials using wave energy or particle radiation on to materials of natural origin of vegetal origin, e.g. cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
Abstract
A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue, it includes wet tissue body and wet tissue liquid, wherein, wet tissue body is the non-woven fabrics for being bonded high molecular quaternary；Wet tissue liquid selective RO purified waters, 12 18 alkyl glucosides, lecithin or hydrolecithin, 1,2 pentanediols, skin conditioning agent, other additives, then the ozone concentration of 0.1 1.0mg/L is passed through in wet tissue liquid, finally, wet tissue liquid is added to wet tissue body by certain weight ratio, pack, that is, form a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue.The product belongs to the wet tissue of zero precipitation preservative, soft to skin, non-stimulated, without allergy, especially suitable for allergy skin, the tender skin of children etc..
Description
Technical field
The present invention relates to a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue, more particularly to a kind of infant
Hip pad wet tissue.
Background technology
In recent years, since the application of wet tissue brings convenience to the life of people, it is increasingly becoming in people's life
Necessity, therefore the annual output of wet tissue and consumption rapid growth, along with the application field of wet tissue constantly expands, corresponding production
The exploitation of product requires also higher and higher.At present, wet tissue species is relatively more, there is hand mouth wet tissue, wet sanitary napkins, makeup-removing wet tissue, clean skin
Wet tissue etc., with the lasting expansion of market scale, national industrial policies encourage wet tissue industry to high-tech, high value added product
Direction is developed, and improves product competitiveness and the market share, therefore the exploitation of wet tissue formula technique will play an important role.
Wet tissue preservative is the topic that consumer especially pays close attention to, and most preservative be all by with cell membrane contact
Afterwards, with some components of cell membrane, mainly with albumen qualitative response, the protection structure or interference cell of microbial cell are destroyed
Metabolism, influences the normal growth order of cell, so as to reach corrosion-resistant purpose, cation is then mainly oozed by influencing it
Pressure thoroughly, makes membranolysis, contraction and dehydration, so as to be sterilized.Mainly there are 3 kinds of modes：1) make microprotein be denatured or
Solidification, there is substantial amounts of protein in microbial body, all factors that can destroy protein spatial configuration, can make protein denaturation or
Solidification.2) enzyme system of microorganism is disturbed, the effect of microorganism endocellular enzyme is related with its active group, all to change or destroy born of the same parents
The material of interior enzymatic activity group function, can suppress the activity of microbial enzyme.3) membrane passage, cationic surface are changed
After activating agent and phenols act on microorganism, membrane structure can be changed, disturb its normal function, so it is dead.
Preservative species used in China's wet tissue industry is various at present, wherein the overwhelming majority is chemical preservative, chemistry
Preservative is because its is simple in structure, the mechanism of action is apparent, property is stable, has a broad antifungal spectrum, cheap and deep liked by wet tissue producer
Love.In fact, some people have found mysterious phenomenon in the user of preservative, the addition of same preservative is
It is several times several years ago, the putrid and deteriorated phenomenon of product still occurs, most of is because certain a kind of (kind) sterilization antiseptic length
Phase is used continuously and causes flora to reduce the sensitiveness of the fungicide, so as to cause antisepsis and sterilization effect to decline, here it is institute
The microorganism of meaning in this case also easily causes consumer skin the feelings such as allergy, stimulation to the resistance to the action of a drug of sterilization antiseptic
Condition.But the continuous improvement and the growing interest to health, people realized with the reach of science, consumer safety are gradually sent out
Chemical preservative in existing wet tissue can produce ill-effect to human body, therefore the requirement that wet tissue preservative uses is also higher and higher,
Wet tissue industry is promoted to begin look for the alternative route of chemical preservative, to reduce the injury to consumer skin.And traditional change
" green ", " health " idea that preservative has been unable to meet people's pursuit are learned, and the appearance of natural antiseptic agent and preservative free is proper
It compensate for this part vacancy well, therefore study and have become mesh using non-stimulated, safe chemical preservative substitute
A kind of trend in preceding daily use chemicals industry.
CN103566371A discloses a kind of antimicrobial method, it is by the organosilicon bi-quaternary ammonium salt of lower formula (I)：
(R1R2R3N+X-) wherein, each R1 independently is C8-18 alkyl, C8-18 alkenyls or C8-18 to-R5- (R1R2R3N+X-) (I)
Alkynyl；Each R2 and R3 independently is methyl or ethyl；R5 is C3-10 alkylidenes, it is in β-position or more distant positions by three (C1-
3 alkoxies) siloxy or three (C1-3 alkoxies) silicyl-C1-6 alkoxies substitution；Independently being with each X- can
Acceptable counter anion, being applied to needs to form antimicrobial membranes on antimicrobial body surface.The physics antimicrobial membranes,
The mould proof of every profession and trade, antibacterial, deodorization are can be widely used for, also can combine to form new combination articles, example with the product of these industries
Such as paper industry, face tissue, hygenic towelette, dixie cup etc..But the wet tissue obtained with this method still has the problem of separating out preservative, resist
Bacterium performance need to be improved, and comfort also has much room for improvement.
CN101716359A discloses a kind of bactericidal disinfectant material, it is will to carry capture bacterium, disease by graft process
The compound of functional group of poison is fixed on nonwoven fabric surface with chemical bond, which includes quaternary ammonium salt, sulfur-containing compound,
Containing the one or more in sulfoacid compound.The bactericidal disinfectant material can be widely used in sterilizing product, such as wet
Towel, cotton balls, disinfection infantees etc..
CN106726636A discloses a kind of physical antibacterial wet tissue, and bi-quaternary ammonium salt is grafted on wet tissue by it by x ray irradiation x
On body, antibiotic property, soft and smooth property and the less antibacterial wet tissue of irritation have been obtained.But the grafting of above-mentioned graft reaction
Rate, and the wet tissue need further to be lifted in antibiotic property, flexibility, smoothness and irritation.
In order to solve the problems, such as wet tissue antibiotic property, flexibility, smoothness difference in the prior art and there is irritating, this hair
Bright to provide a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue, its effect is by positively charged anti-micro- life
Thing film or particle produce electrostatic force with negatively charged microbial cell film and make it that microbial cell film ruptures or form changes
Become and cause microorganism dead, so as to be provided with anti-corrosive antibacterial ability, the product strong antibacterial, flexibility and smoothness are good,
It is soft to skin, non-stimulated, without allergy, especially suitable for allergy skin, the tender skin of children etc..
The content of the invention
The present invention provides a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue.The wet tissue includes wet tissue sheet
Body and wet tissue liquid, wet tissue body have selected with antimicrobial membranes or the non-woven fabrics of nano particle with positive charge, this is anti-
Microbial film or nano particle are formed by chemical bonds；Wet tissue liquid selective RO purified waters, 12-18 alkyl glucosides
Glycosides, lecithin or hydrolecithin, 1,2- pentanediols, skin conditioning agent, other additives, are then passed through in wet tissue liquid
The ozone concentration of 0.1-1.0mg/L, finally, is added to wet tissue body by certain weight ratio by wet tissue liquid, packs, i.e. shape
Into a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue.
Specifically, the present invention provides a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue, it is by wet tissue
Body and wet tissue liquid composition, the wet tissue body is the non-woven fabrics for being bonded high molecular quaternary；The wet tissue liquid be by
It is following to be formed with each component of percentage by weight：
RO purified waters 65-70%
12-18 alkyl glucosides 0.1-0.6%
Lecithin or hydrolecithin 0.2-0.5%
1,2- pentanediol 25-30%
Skin conditioning agent 0.2-2%
Other additives 1-6%,
The sum of each component content is 100%.
Wherein, the preparation method of wet tissue body is：
(1) length is used as 40-50mm, and the bamboo pulp fiber of a diameter of 0.04-0.1mm is as raw material, through cross lapping water
Bamboo pulp non-woven fabrics is made after piercing technique, the nonwoven carrier that thickness is 3-5mm is obtained after clipped, high-temperature sterilization；
(2) nonwoven carrier made from step (1) is placed in the monomer solution of isopropanol/water mixed solvent preparation, room
When the lower lucifuge immersion 12-24 of temperature is small；
(3) under nitrogen protection, CeCl is added in monomer solution3/ HCl/water solution, with x ray irradiation x above-mentioned steps (2)
In it is soaking after obtained non-woven fabrics, irradiation intensity 80-200KGy；
(4) after irradiating, unreacted monomer and homopolymer are fallen in extracting, and wet tissue body is obtained after dry；
Wherein, monomer is organosilicon bi-quaternary ammonium salt and acrylamide, the quality point of organosilicon bi-quaternary ammonium salt in monomer solution
Number is 0.2-0.3%, and the molar ratio of organosilicon bi-quaternary ammonium salt and acrylamide is (10-20): 1；CeCl3In the reaction system
Initial concentration be (1-2) × 10-4The initial concentration of mol/L, HCl in the reaction system is (1-2) × 10-3mol/L；
The organosilicon bi-quaternary ammonium salt is the compound shown in formula 1 or formula 2：
The ray is selected from ultraviolet, electron beam, X-ray, alpha ray, β rays or gamma-rays；
The skin conditioning agent is ceramide, one kind in Co-Q10, tocopherol acetate, resveratrol, astaxanthin
It is or a variety of.
Other described additives are antioxidant, one or more kinds of mixtures in chelating agent, pH adjusting agent,
It is chosen in particular from one or more kinds of in Butylated Hydroxytoluene, EDTA-2Na, EDTA-4Na, arginine, citric acid, sodium citrate
Mixture.
The 12-18 alkyl glucosides are lauryl glucoside or octadecyl glucoside.
Present invention also offers a kind of preparation method of wet tissue liquid, it is characterised in that wet tissue liquid is the shield of transparent and stable
Skin lotion, this method comprises the following steps：
(1) 12-18 alkyl glucosides 0.1-0.6%, lecithin or hydrolecithin 0.2-0.5% are mixed and heated
To 50-80 DEG C, at this temperature, 5-20min is quickly stirred, to obtaining clear solution A；
(2) RO purified waters 65-70%, 1,2- pentanediols 25-30%, other additives 1-6% are mixed and heated to 60-
90 DEG C, it is evenly stirred until clear solution B；
(3) under high-speed stirred, B solution is slowly added in solution A, until obtaining clear solution C；
(4) C solution that cools down adds skin conditioning agent 0.2-2%, stirs evenly and clear solution D is made to less than 45 DEG C；
(5) ozone is passed through in solution D, ozone concentration is maintained in the range of 0.1-1.0mg/L, up to wet tissue liquid E.
Further, present invention also offers a kind of preparation of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue
Method, it is characterised in that add the ratio of wet tissue liquid E and the wet tissue body by weight 1.5: 1-4: 1 for being cut into suitable dimension
Add, then pack, up to acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue.
The acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue of the present invention has the work killed or suppress microorganism
With its is safe to the human body, and can be produced to avoid drug resistance caused by chemical antibiotic antiseptic., should compared with traditional wet tissue
Wet tissue has the following advantages that：
1st, traditional wet tissue is that antiseptic is fixed in non-woven fabrics using adhesive, and the wet tissue is by stable chemistry
Bond is the product of zero precipitation preservative together in non-woven fabrics；
2nd, traditional wet tissue anti-corrosion function is protection structure or the metabolism of interference cell by destroying microbial cell,
The normal growth order of cell is influenced, so as to reach corrosion-resistant purpose.And the wet tissue anti-corrosion function is resisted by positively charged
Microbial film or nano particle make the rupture of microbial cell film dead with negatively charged microbial film by electrostatic force, from
And reach anti-corrosive antibacterial function.
4th, chemical preservation antiseptic wet tissue imposes on human body surface for a long time may cause the symptoms such as human allergy, make as excessive
With may result in dermatitis, spot, or even DNA damage can be caused.In addition, during production, variation bacterium or tolerance are also easily grown
Bacterium, unpredictable security risk problem is added for company, and the application of the wet tissue completely avoid above-mentioned unfavorable factor.
5th, by CeCl3Make specific organosilicon bi-quaternary ammonium salt and acrylamide graft under/HCl initiation systems in wet tissue
On body, the grafting rate of organosilicon bi-quaternary ammonium salt is improved, only excellent antibacterial effect is can reach with seldom amount of monomer, makes
The antibacterial effect of the wet tissue has exceeded common antibacterial wet tissue of the prior art, and wet tissue has splendid flexibility and smooth
Property, uses extremely gentle and nonirritant, drug resistance will not be produced, available for infant's hip pad wet tissue, infant's hand mouth
Wet tissue, clean skin wet tissue and wet sanitary napkins etc., the wet tissue can be rapidly to skin problems such as dermatitis, eczema, bedsore, the red hip of baby
Act, there is bacterio static itching-relieving, the positive effect of skin care, be particularly suitable for using during the red hip of baby.
Brief description of the drawings
Fig. 1 is the nuclear magnetic spectrogram of organosilicon bi-quaternary ammonium salt A described in preparation example 1.
Fig. 2 is the nuclear magnetic spectrogram of organosilicon bi-quaternary ammonium salt B described in preparation example 2.
Embodiment
Preparation example 1：
1) dry hydrogen chloride gas is imported in the anhydrous ether solution of octadecyldimethyl tertiary amine, it is heavy produces white
Form sediment.Then using water as solvent, epoxychloropropane is placed in dropping funel, starts to be slowly added dropwise, 35min is dripped off, and is stirred at room temperature
After mixing uniformly, 12h is reacted in 80 DEG C, reaction end is determined by titrating epoxychloropropane quaternary ammonium salt content, after completion of the reaction,
Rotary evaporation removes solvent at room temperature, faint yellow paste residue is obtained, with acetone recrystallization paste residue, crystal to be separated out
Decompression filters afterwards, is so repeated several times, and finally obtains white powder mono-quaternaries product --- intermediate product N- (the chloro- 2- hydroxypropyls of 3-
Base)-N, N- dimethyl stearyl ammonium chlorides.Wherein, octadecyldimethyl tertiary amine: hydrogen chloride: mole of epoxychloropropane
Than for 1.5: 1.2: 1.
2) N, N- dimethyl -1,2- are sequentially added in the four-hole boiling flask equipped with electric mixer, thermometer and still
Ethylenediamine, methyl oleate, dibutyl tin dilaurate, hydroquinone, are warming up to 110 DEG C, when back flow reaction 4 is small.Then will be anti-
Answer device to be changed to distilling apparatus, continue to stir, be distilled off at the reaction temperatures unreacted methyl oleate and its with methanol
Azeotropic mixture.Stop reaction, vacuum distillation, vacuum drying obtain oleoyl ethyldimethyl amine.Wherein, N, N- dimethyl -1,2- second
The molar ratio of diamines and methyl oleate is 1: 4, and dibutyl tin dilaurate, the dosage of hydroquinone are respectively reaction solution gross mass
2% and 0.1%.
3) products therefrom in step 1) is sequentially added in the four-hole boiling flask equipped with electric mixer, thermometer and still
I, acetone, hydroquinone.Heating water bath adds step 2) products therefrom II, when reaction 4 is small to 60 DEG C.Filter and remove solvent, not
The raw material and hydroquinone of reaction, crystallisation by cooling, filters to obtain product III.With acetone recrystallization 3-4 times, vacuum drying.Wherein,
The molar ratio of product I and II are 1: 4, the dosage of hydroquinone, are the 0.15% of reaction solution gross mass
4) by products therefrom III in step 3) and γ-chloropropyl pi-allyl diethoxy silane under the conditions of being stirred at reflux
60 DEG C are warming up to, reacts 24h, vacuum distillation removes residue, then the dry 24h of 40 DEG C of vacuum, up to organosilicon bi-quaternary ammonium salt
A。
Preparation example 2：
It is identical with preparation example 1, differ only in：The anhydrous ether of Dodecyl Dimethyl Amine is used in the 1) step
Solution, finally obtains organosilicon bi-quaternary ammonium salt B.
Embodiment 1
The preparation method of wet tissue body is：
(1) length is used as 45mm, and the bamboo pulp fiber of a diameter of 0.07mm is as raw material, after cross lapping water jet process
Bamboo pulp non-woven fabrics is made, the nonwoven carrier that thickness is 4mm is obtained after clipped, high-temperature sterilization；
(2) nonwoven carrier made from step (1) is placed in the monomer solution of 1L isopropanol/waters mixed solvent configuration,
When lucifuge immersion 18 is small at room temperature, wherein monomer is organosilicon bi-quaternary ammonium salt A and acrylamide, organosilicon bi-quaternary ammonium salt in solution
The mass fraction of A is 0.2%, and the molar ratio of organosilicon bi-quaternary ammonium salt A and acrylamide is 15: 1, the volume of isopropanol and water
Than for 3: 1；
(3) under nitrogen protection, CeCl is added in monomer solution3/ HCl/water solution, with gamma-ray irradiation above-mentioned steps
(2) in it is soaking after obtained non-woven fabrics, irradiation intensity 90KGy；CeCl3Initial concentration in the reaction system is 2 × 10-4The initial concentration of mol/L, HCl in the reaction system is 1 × 10-3mol/L；
(4) after irradiating, unreacted monomer and homopolymer are fallen in extracting, and wet tissue body is obtained after dry；
In the preparation process of wet tissue liquid E, solution A selects lauryl glucoside 0.1g, lecithin 0.5g.Solution B is selected
1,2- pentanediol 25g, EDTA-2Na 6g, RO purified water 66.4g.Skin conditioning agent selects water-soluble Cer NS g.
Specially：
1) lauryl glucoside 0.1g, lecithin 0.5g are mixed and heated to 60 DEG C, at this temperature, quickly stirred
15min, to obtaining clear solution A.
2) 1,2- pentanediols 25g, EDTA-2Na 6g, RO purified water 66.4g is mixed and heated to 70 DEG C, stirred evenly
To clear solution B.
3) under high-speed stirred, B solution is slowly added in solution A, until clear solution C is obtained,
4) C solution that cools down adds water-soluble Cer NS g, stirs evenly and clear solution D is made to 40 DEG C.
5) ozone is passed through in solution D, ozone concentration is maintained at 0.3mg/L, up to wet tissue liquid E.
The ratio of above-mentioned wet tissue liquid E and wet tissue body by weight 4: 1 is added, is then packed, up to acryloyl
Amine organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue.
Embodiment 2
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with organosilicon bi-quaternary ammonium salt B.
Embodiment 3
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except the mass fraction of organosilicon bi-quaternary ammonium salt A is replaced with 0.3%.
Embodiment 4
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except the mass fraction of organosilicon bi-quaternary ammonium salt A is replaced with 0.25%.
Embodiment 5
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except the molar ratio of organosilicon bi-quaternary ammonium salt A and acrylamide are replaced with 10: 1.
Embodiment 6
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except the molar ratio of organosilicon bi-quaternary ammonium salt A and acrylamide are replaced with 20: 1.
Embodiment 7
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except gamma-rays is replaced with ultraviolet.
Embodiment 8
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except by soaking time replace with 12 it is small when, irradiation intensity replaces with 200KGy.
Embodiment 9
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 2 is identical, and except lauryl glucoside is replaced with octadecyl glucoside, lecithin replaces with hydrolecithin.
Embodiment 10
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 2 is identical, except ozone concentration is maintained at 1.0mg/L.
Embodiment 11
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except the ratio of wet tissue liquid E and wet tissue body by weight 1.5: 1 is added.
Embodiment 12
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, and except the dosage of lauryl glucoside replaced with 0.6g, the dosage of lecithin replaces with 0.5g, and 1,2- penta
The dosage of glycol replaces with 30g, and the dosage of EDTA-2Na replaces with 1g, RO purified waters 67.7g, the use of water-soluble ceramide
Amount replaces with 0.2g.
Embodiment 13
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, and except the dosage of lauryl glucoside replaced with 0.3g, the dosage of lecithin replaces with 0.4g, and 1,2- penta
The dosage of glycol replaces with 28g, and the dosage of EDTA-2Na replaces with 3g, RO purified waters 67.3g, the use of water-soluble ceramide
Amount replaces with 1g.
Comparative example 1
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except the mass fraction of organosilicon bi-quaternary ammonium salt A is replaced with 0.1%.
Comparative example 2
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except monomer is only organosilicon bi-quaternary ammonium salt A.
Comparative example 3
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except being added without CeCl3/ HCl/water solution.
Comparative example 4
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with dimethyldiallylammonium salt.
Comparative example 5
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with N- methylacryoyloxyethyls-N, N- dimethylammonium-α-N- first
Base carboxybetaine.
Comparative example 6
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with oleamide Ethyldimethylaminopropyl methyl dimethoxysilane
Quaternary ammonium salt.
Comparative example 7
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with 2- triethoxysilicanes propane Oxy-1-octadecylene base-3- ten
Eight alkyl dimethyl ammonium propane dichloride.
Comparative example 8
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with 2- triethoxysilicanes propane Oxy-1-octenyl-3- 18
Alkyl dimethyl ammonium propane dichloride.
Comparative example 9
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with 2- triethoxysilicanes propane Oxy-1-laurylene base-3- ten
Eight alkyl dimethyl ammonium propane dichloride.
Comparative example 10
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with 2- triethoxysilicane propane Oxy-1-N, N- dimethyl allenes
Acyl group -3- octadecyldimethyl ammonium propane dichloride.
Comparative example 11
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except organosilicon bi-quaternary ammonium salt A is replaced with 2- triethoxysilicane propane Oxy-1-N, N- dimethyl allenes
Acyl group -3- dodecyl dimethyl ammonium propane dichloride.
Comparative example 12
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except monomer solution is replaced with 2- triethoxysilicane propane the Oxy-1s-N, N- that mass fraction is 0.2%
The solution of Dimethylacryloyl -3- octadecyldimethyl ammonium propane dichloride.
Comparative example 13
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except monomer solution is replaced with 2- triethoxysilicane propane the Oxy-1s-N, N- that mass fraction is 0.2%
The solution of Dimethylacryloyl -3- dodecyl dimethyl ammonium propane dichloride.
Comparative example 14
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except 1,2- pentanediols are replaced with 1,5-PD.
Comparative example 15
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except 1,2- pentanediols are replaced with 1,2-PD.
Comparative example 16
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, and except the dosage of 1,2- pentanediols is replaced with 22g, the dosage of RO purified waters replaces with 69.4g.
Comparative example 17
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, and except the dosage of 1,2- pentanediols is replaced with 33g, the dosage of RO purified waters replaces with 65g, EDTA-2Na
Dosage replace with 1g, the dosage of water-soluble ceramide replaces with 0.4g.
Comparative example 18
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except lecithin is replaced with lanolin.
Comparative example 19
The preparation method of wet tissue body, wet tissue liquid E and acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue with
Embodiment 1 is identical, except lauryl glucoside is replaced with sodium cocoyl glutamate.
Technique effect：
1. fungistatic effect
By the evaluation criterion testing example in Disposable Sanitary Accessory sanitary standard GB15979-2002 appendix Cs and
The bacteriostasis rate of wet tissue, test result are as shown in table 1 in comparative example：
The fungistatic effect of 1 wet tissue of table
It can be seen from the data in table 1 compared with the wet tissue in comparative example, wet tissue product of the invention has more excellent
Anti-microbial property.
2. soft and smooth property
Group is evaluated using 5 people to evaluate the soft and smooth property of wet tissue in embodiment and comparative example by ten point system, is surveyed
Test result is as shown in table 2：
The soft and smooth property of 2 wet tissue of table
It can be seen from the data in table 2 compared with the wet tissue in comparative example, wet tissue product of the invention has more excellent
Softness and smoothness.
3. irritation
Foundation《Disinfection technology standard》In an intact skin stimulation test to wet tissue carry out skin irritation detection, test
The results are shown in Table 3：
The irritation of 3 wet tissue of table
Standards of grading：
Erythema is formed：0 is nothing, and 1 is, reluctantly as it can be seen that 2 be obvious, 3 is serious, and 4 be aubergine erythema, and has eschar；
Oedema is formed：0 is nothing, and 1 swells about 1mm for reluctantly as it can be seen that 2 be cutaneous protuberance, profile understands, 3 for oedema, and 4 are
Oedema is swelled more than 1mm.
It can be seen from the data in table 3 compared with the wet tissue in comparative example 4-19, wet tissue product of the invention has more
Small irritation.
4. comfort level
Wet tissue in above-described embodiment and comparative example is used 10 days to red hip baby, the effect such as institute of table 4 after use
Show：
The red hip baby of table 4 uses wet tissue effect
It can be seen from the data in table 4 compared with the wet tissue in comparative example, the thing to red hip baby using the present invention
After managing antibiotic and sterilizing wet tissue, sufferer improves significantly, suitable for promoting and applying.
Claims (10)
1. a kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue, it is made of wet tissue body and wet tissue liquid, institute
It is the non-woven fabrics for being bonded high molecular quaternary to state wet tissue body；The wet tissue liquid is by following each groups with percentage by weight
Part composition：
RO purified waters 65-70%
12-18 alkyl glucosides 0.1-0.6%
Lecithin or hydrolecithin 0.2-0.5%
1,2- pentanediol 25-30%
Skin conditioning agent 0.2-2%
Other additives 1-6%,
The sum of each component content is 100%；
Wherein, the preparation method of wet tissue body is：
(1) length is used as 40-50mm, and the bamboo pulp fiber of a diameter of 0.04-0.1mm is as raw material, through cross lapping spun lacing work
Bamboo pulp non-woven fabrics is made after skill, the nonwoven carrier that thickness is 3-5mm is obtained after clipped, high-temperature sterilization；
(2) nonwoven carrier made from step (1) is placed in the monomer solution of isopropanol/water mixed solvent preparation, at room temperature
When lucifuge immersion 12-24 is small；
(3) under nitrogen protection, CeCl is added in monomer solution3/ HCl/water solution, with warp in x ray irradiation x above-mentioned steps (2)
The non-woven fabrics obtained after immersion, irradiation intensity 80-200KGy；
(4) after irradiating, unreacted monomer and homopolymer are fallen in extracting, and wet tissue body is obtained after dry；
Wherein, monomer is organosilicon bi-quaternary ammonium salt and acrylamide, and the mass fraction of organosilicon bi-quaternary ammonium salt is in monomer solution
0.2-0.3%, and the molar ratio of organosilicon bi-quaternary ammonium salt and acrylamide is (10-20): 1；CeCl3At the beginning of in the reaction system
Beginning concentration is (1-2) × 10-4The initial concentration of mol/L, HCl in the reaction system is (1-2) × 10-3mol/L；
The organosilicon bi-quaternary ammonium salt is the compound shown in formula 1 or formula 2：
2. acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as claimed in claim 1, wherein, the ray is selected from
Ultraviolet, electron beam, X-ray, alpha ray, β rays or gamma-rays.
3. acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as claimed in claim 1, wherein, the skin condition
Agent is ceramide, the one or more in Co-Q10, tocopherol acetate, resveratrol, astaxanthin.
4. acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as claimed in claim 1, wherein, other described add
Add agent for one or more kinds of mixtures in antioxidant, chelating agent, pH adjusting agent.
5. the acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as described in claim 1 or 4, wherein, it is described other
One or more of the additive in Butylated Hydroxytoluene, EDTA-2Na, EDTA-4Na, arginine, citric acid, sodium citrate
Mixture.
6. acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as claimed in claim 1, wherein, the 12-18 alkane
Base glucoside is lauryl glucoside.
7. acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as claimed in claim 1, wherein, the 12-18 alkane
Base glucoside is octadecyl glucoside.
8. the preparation side of the acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue as described in claim 1-7 any one
Method, it is characterised in that：
The preparation method of wet tissue body is：
(1) length is used as 40-50mm, and the bamboo pulp fiber of a diameter of 0.04-0.1mm is as raw material, through cross lapping spun lacing work
Bamboo pulp non-woven fabrics is made after skill, the nonwoven carrier that thickness is 3-5mm is obtained after clipped, high-temperature sterilization；
(2) nonwoven carrier made from step (1) is placed in the monomer solution of isopropanol/water mixed solvent preparation, at room temperature
When lucifuge immersion 12-24 is small；
(3) under nitrogen protection, CeCl is added in monomer solution3/ HCl/water solution, with warp in x ray irradiation x above-mentioned steps (2)
The non-woven fabrics obtained after immersion, irradiation intensity 80-200KGy；
(4) after irradiating, unreacted monomer and homopolymer are fallen in extracting, and wet tissue body is obtained after dry；
Wherein, monomer is organosilicon bi-quaternary ammonium salt and acrylamide, and the mass fraction of organosilicon bi-quaternary ammonium salt is in monomer solution
0.2-0.3%, and the molar ratio of organosilicon bi-quaternary ammonium salt and acrylamide is (10-20): 1；CeCl3At the beginning of in the reaction system
Beginning concentration is (1-2) × 10-4The initial concentration of mol/L, HCl in the reaction system is (1-2) × 10-3mol/L；
The organosilicon bi-quaternary ammonium salt is the compound shown in formula 1 or formula 2：
Wet tissue liquid is the facial treatment milk of transparent and stable, and its preparation method is：
(1) 12-18 alkyl glucosides 0.1-0.6%, lecithin or hydrolecithin 0.2-0.5% are mixed and heated to 50-
80 DEG C, at this temperature, 5-20min is quickly stirred, to obtaining clear solution A；
(2) RO purified waters 65-70%, 1,2- pentanediols 25-30%, other additives 1-6% are mixed and heated to 60-90
DEG C, it is evenly stirred until clear solution B；
(3) under high-speed stirred, B solution is slowly added in solution A, until obtaining clear solution C；
(4) C solution that cools down adds skin conditioning agent 0.2-2%, stirs evenly and clear solution D is made to less than 45 DEG C；
(5) ozone is passed through in solution D, ozone concentration is maintained in the range of 0.1-1.0mg/L, up to wet tissue liquid E；
Finally, the ratio of wet tissue liquid E and the wet tissue body by weight 1.5: 1-4: 1 for being cut into suitable dimension is added, then
Pack, up to acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue.
9. preparation method as claimed in claim 8, wherein ozone concentration are in 0.1-0.5mg/L scopes.
10. preparation method as claimed in claim 8, wherein wet tissue liquid E are with being cut into the wet tissue body of suitable dimension by weight
The ratio addition of amount 2: 1-3: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711094247.4A CN107898651A (en) | 2017-11-09 | 2017-11-09 | A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711094247.4A CN107898651A (en) | 2017-11-09 | 2017-11-09 | A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107898651A true CN107898651A (en) | 2018-04-13 |
Family
ID=61843795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711094247.4A Pending CN107898651A (en) | 2017-11-09 | 2017-11-09 | A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107898651A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113698444A (en) * | 2021-08-25 | 2021-11-26 | 太和县芮欣生物科技有限公司 | Cationic alkyl glycoside quaternary ammonium salt surfactant and preparation process thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1978501A (en) * | 2006-12-08 | 2007-06-13 | 北京化工大学 | UV-induced polymer surface modifying method |
| CN101716359A (en) * | 2009-12-08 | 2010-06-02 | 北京欧凯纳斯科技有限公司 | Sterilization and pasteurization material and application thereof |
| CN103566371A (en) * | 2012-08-01 | 2014-02-12 | 南京神奇科技开发有限公司 | Antimicrobial physical method |
| CN106038356A (en) * | 2016-07-04 | 2016-10-26 | 苏州宝丽洁日化有限公司 | Physical antibacterial wet wipe and preparation method thereof |
| CN106726636A (en) * | 2017-02-17 | 2017-05-31 | 苏州宝丽洁日化有限公司 | A kind of physical antibacterial wet tissue |
| CN106860029A (en) * | 2017-02-17 | 2017-06-20 | 苏州宝丽洁日化有限公司 | A kind of physical antibacterial wet tissue |
-
2017
- 2017-11-09 CN CN201711094247.4A patent/CN107898651A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1978501A (en) * | 2006-12-08 | 2007-06-13 | 北京化工大学 | UV-induced polymer surface modifying method |
| CN101716359A (en) * | 2009-12-08 | 2010-06-02 | 北京欧凯纳斯科技有限公司 | Sterilization and pasteurization material and application thereof |
| CN103566371A (en) * | 2012-08-01 | 2014-02-12 | 南京神奇科技开发有限公司 | Antimicrobial physical method |
| CN106038356A (en) * | 2016-07-04 | 2016-10-26 | 苏州宝丽洁日化有限公司 | Physical antibacterial wet wipe and preparation method thereof |
| CN106726636A (en) * | 2017-02-17 | 2017-05-31 | 苏州宝丽洁日化有限公司 | A kind of physical antibacterial wet tissue |
| CN106860029A (en) * | 2017-02-17 | 2017-06-20 | 苏州宝丽洁日化有限公司 | A kind of physical antibacterial wet tissue |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113698444A (en) * | 2021-08-25 | 2021-11-26 | 太和县芮欣生物科技有限公司 | Cationic alkyl glycoside quaternary ammonium salt surfactant and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106038356B (en) | A kind of physical antibacterial wet tissue and preparation method thereof | |
| CN109381480B (en) | Compound polyhexamethylene biguanide disinfectant and preparation method thereof | |
| CN106726636A (en) | A kind of physical antibacterial wet tissue | |
| CN109381363A (en) | A kind of amino acid shampoo and preparation method thereof | |
| CN105209049B (en) | Antimicrobial compositions and its manufacturing method | |
| CN106860029B (en) | Physical antibacterial wet tissue | |
| CN110327282A (en) | A kind of dandruff control shampoo containing and preparation process improving scalp epidermis microbial flora | |
| CN113117137A (en) | Medical dressing containing recombinant human collagen and preparation method thereof | |
| US20200297605A1 (en) | Biome-friendly consumer products | |
| JPWO2009069619A1 (en) | Novel composition containing ozonized surfactant | |
| CN104887578A (en) | Silicon-oil-free composition with scalp care function and hair conditioner | |
| CN107929104A (en) | A kind of three-in-one wash and maintenance liquid of biology enzyme and preparation method thereof | |
| CN115317392B (en) | Oil-control anti-dandruff amino acid shampoo and preparation method thereof | |
| CN107320362A (en) | All Pure Nature, support, protect, washing comprehensive, noresidue goes to remain shampoo | |
| CN110974717B (en) | Moisturizing baby wet tissue capable of removing dirt and preparation method thereof | |
| KR102272901B1 (en) | Composition for external application to the skin containing meso-2,3-butanediol as a preservative | |
| JP2020164548A (en) | Composition containing meso-2,3-butanediol | |
| US20200297619A1 (en) | Biome-friendly consumer products | |
| TWI329640B (en) | Use of substituted 2,4-bis(alkylamino)pyrimidines | |
| CN107898651A (en) | A kind of acrylamide organosilicon bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof | |
| CN109512741A (en) | A kind of essential oil is washed one's hands condensation and preparation method thereof | |
| CN109528526A (en) | Plant essence skin conditioning agent and preparation method thereof and oil control and acne removal application | |
| CN107440925A (en) | A kind of compound method of disposable hand sanitizing fluid | |
| CN107789214A (en) | A kind of acrylic acid bi-quaternary ammonium salt grafted nonwoven fabric wet tissue and preparation method thereof | |
| CN104207970A (en) | Medical skin-care disinfection hand-cleaning liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180413 |